Apr 30 |
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
|
Apr 30 |
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
|
Apr 29 |
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
|
Apr 29 |
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
|
Apr 29 |
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
|
Apr 28 |
11 Oversold Growth Stocks to Buy Right Now
|
Apr 25 |
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
|
Apr 25 |
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
|
Apr 25 |
Regeneron (REGN) Reports Next Week: What You Should Expect
|
Apr 25 |
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
|